PDE5 inhibitors, which have been certified for the treatment of erectile dysfunction, pulmonary hypertension, LUTSs associated with BPH, and penile rehabilitation after radical prostatectomy, are all taken by mouth, absorbed in the small intestine, and metabolized in the liver via CYP3A pathway [46]. This evidence concerns the gene CYP3A4 and benign prostatic hyperplasia.